NCT02745184View on ClinicalTrials.gov

Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BIOLOGICAL

Lung stem cells

Patients will receive 0.5-5x10\^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.

Trial Locations (1)

200123

Shanghai East Hospital, Shanghai

All Listed Sponsors
collaborator

Regend Therapeutics

INDUSTRY

lead

Shanghai East Hospital

OTHER

NCT02745184 - Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter